Catalysts / JSPR
Upcoming FDA decisions and readouts we track for Jasper Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Jasper Therapeutics (JSPR, listed on Nasdaq). They cover 2 programmes: KP-104 (Rare renal indications (complement inhibitor)) and Briquilimab (Chronic spontaneous urticaria / mast cell disease).
First on the list: the Phase 2 readout for KP-104 (Rare renal indications (complement inhibitor)), guided by the company to Q4 2026. By stage, the upcoming rows are 1 Phase 2 readout and 1 Regulatory milestone.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4; Why catalyst windows like "H2 2026" are vague, and how they narrow.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Jasper Therapeutics JSPR · Nasdaq | KP-104 | Rare renal indications (complement inhibitor) | Q4 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Jasper Therapeutics JSPR · Nasdaq | Briquilimab | Chronic spontaneous urticaria / mast cell disease | Q1 2027 company guidance |
Regulatory milestone | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList